Zota Health Care Ltd Q4 FY2026 Concall Summary & Transcript Notes

Source transcript PDF: https://www.stockscans.in/document/p2v3xhtswn0xe2zao84yp3bb.pdf

# 1. Financial Performance

## A. Key Figures
   *   **Revenue:** **₹538.65 Cr** consolidated (+83.86% YoY) · **₹407 Cr** standalone
   *   **Gross Profit:** **₹324.68 Cr** (+108% YoY) · **60.28%** margin (+714 bps)
   *   **EBITDA:** **₹25.97 Cr** FY26 (4.82% margin) · **₹11.91 Cr** Q4 FY26 (7.3% margin)
   *   **GMV:** **₹93 Cr** for quarter ending May 2026
   *   **Capex:** **₹114 Cr** annual expenditure

## B. Revenue Growth
   *   **Network Expansion:** Exceptional top-line momentum driven by the Davaindia network build-out and robust same-store sales growth.
   *   **Operating Leverage:** Near-doubling of sales allowed the company to absorb higher absolute marketing and branding spend without compromising the cost structure.
   *   **Growth Outlook:** Management targets a **30% growth rate** on the current base, which is expected to add **INR 120 Cr** in incremental revenue and enhance profitability.

## C. Margins & Profitability
   *   **Structural Margin Expansion:** Gross margins reached multi-year highs due to a **100% private label portfolio** and a vertically integrated manufacturing-to-retail model.
   *   **Profitability Turnaround:** Shifted from negative to positive EBITDA in FY26, with exit-quarter margins showing significant sequential improvement.
   *   **Sustainability:** Current margin levels are deemed sustainable with further upside potential as the company achieves greater economies of scale across COCO and FOFO formats.

## D. Balance Sheet & Capital Allocation
   *   **Capital Raise:** Successfully completed a **₹350 Cr** Qualified Institutional Placement (QIP) to fortify the balance sheet for future scaling.
   *   **Asset Development:** Intangible assets include **INR 14 Cr** in pre-operative expenses for new stores, covering regulatory approvals and drug licenses.
   *   **Inventory Strategy:** Increased inventory levels and capital expenditure reflect aggressive preparations for upcoming store launches.

---

# 2. Operating Segments

## A. Key Figures
   *   **Davaindia Revenue:** **₹417.41 Cr** FY26 (+100% YoY) · **77%** of Total Revenue
   *   **Segment Mix:** **13%** Domestic Formulations · **6%** Exports · **3%** Everyday Herbal
   *   **Gross Margin (Davaindia):** **~70%** Recent Quarter
   *   **Store Network:** **2,579** Total Stores (+997 YoY) · **1,656** COCO · **923** FOFO
   *   **Subsidiary Stake:** **87.78%** in Everyday Herbal Beauty Care Limited

## B. Davaindia Performance
   *   **Primary Growth Engine:** The retail business has emerged as the dominant revenue contributor, with top-line performance doubling year-over-year.
   *   **Operational Transparency:** Financials utilize arm's length pricing for all store transactions; consolidated figures account for inter-company eliminations to reflect true market scale.
   *   **Strategic Mission:** Focus remains on disrupting the pharmaceutical landscape by providing affordable healthcare across urban and rural India.

## C. Store Network Expansion
   *   **Record-Breaking Scaling:** Management achieved the highest-ever annual store addition in the pharma retail segment, significantly expanding the national footprint.
   *   **Model Shift Toward COCO:** Future expansion is heavily weighted toward the Company-Owned model (**80%-90%** of pipeline), targeting **500+** new COCO units.
   *   **Operational Stability:** Zero COCO store closures in the past year indicate high site-selection efficacy and retail model sustainability.
   *   **Near-Term Pipeline:** Following a strong Q4, the company expects to maintain momentum with **200+** additional store openings in the current quarter.

## D. B2B & New Platforms
   *   **Supply Chain Disruption:** New platforms like **UGO Generic** (B2B) and **All Day** stores are designed to capture market share by catering directly to existing retail pharmacies.
   *   **Ecosystem Synergy:** These models complement the core retail brand, aiming to accelerate consumer reach and streamline medicine affordability.

## E. Subsidiary Integration
   *   **Backward Integration:** Increased ownership in Everyday Herbal Beauty Care strengthens control over the consumer product portfolio and manufacturing supply chain.
   *   **Consolidation Dynamics:** The **INR 132 Cr** variance between standalone and consolidated figures is primarily attributed to Davaindia operations and necessary internal eliminations.

---

# 3. Customer Metrics

## A. Key Figures
   *   **Same-Store Growth (SSG):** **>40%** for 852 stores (post-March 2025) · **24%** for 234 mature stores (adjusted for GST) · **17%** for 29 oldest stores (adjusted for GST)
   *   **Monthly GMV per Store:** **₹1.42 lakh** (new cohort) · **₹4.5–4.7 lakh** (39–54 month cohort) · **~₹7 lakh** (most mature cohort)
   *   **Customer Wallet Spend:** **₹230** average · **₹270–290** mature stores
   *   **Annual Footfalls:** **1.82 Cr+** (+100% YoY)
   *   **Total GMV:** **₹457.06 Cr**

## B. Same-Store Growth & Operational Trends
   *   **Outsized Retail Performance:** Mature store growth significantly exceeds the retail sector's typical high-single-digit benchmark, driven by a ramp-up in stores with **1-2 years** of vintage.
   *   **Vintage-Based Momentum:** Newer stores (12-24 months) are seeing the highest velocity of growth, while the oldest cohorts maintain robust double-digit annualized momentum.
   *   **Normalized Growth Trajectory:** Reported flattish quarterly trends were impacted by **fewer operating days (90 vs 92)**; adjusting for this, effective growth remains strong at an annualized rate of **15-20%**.

## C. Cohort Analysis & Maturity Scaling
   *   **Maturity-Driven Revenue:** Store productivity scales aggressively with age; the most mature locations generate nearly **5x** the monthly GMV of the newest store cohorts.
   *   **GST Impact Neutralization:** Underlying performance in the oldest cohorts is stronger than reported figures suggest, as a **7%** headwind from GST reductions masked true organic growth.
   *   **Unit Economics:** Rapid network expansion is improving unit economics as the broader store base matures and customer engagement doubles.

## D. Wallet Spend & Footfall
   *   **Stable Consumer Spend:** Average wallet share has remained resilient despite the rapid addition of **220 stores** in the latest quarter.
   *   **Spend Deepening:** As stores age, they successfully capture a higher share of the consumer's wallet, moving from initial lower levels to a peak of nearly **₹300** per visit.

---

# 4. Strategic Initiatives

## A. Key Figures
*   **Advertising Expenditure:** **₹18 Cr** Current FY (+71%) · **₹10.5 Cr** Previous FY
*   **Sales Growth:** **80%-90%** Year-on-Year

## B. Brand & Marketing
*   **High-Profile Brand Portfolio:** Strategic visibility bolstered by multi-year associations with **MS Dhoni** and **Suniel Shetty** for Davaindia, alongside the recent onboarding of **Akshay Kumar** for the UGO Generic platform.
*   **Marketing Efficiency:** Absolute ad spend increased significantly but remains rationalized and proportional to the robust top-line expansion.
*   **Omnichannel Amplification:** Current efforts focus on TVCs with MS Dhoni, cinema screen advertisements, and bus panel branding across Tier-1 hubs like **Mumbai, Pune, and Bangalore**.
*   **Sustainable Brand Identity:** Management is eschewing aggressive short-term TV saturation in favor of a "sustainable consumer movement" to ensure long-term brand stability.

## C. Expansion & 1,000-Day Plan
*   **Strategic Roadmap:** Launch of the **UGO Generic** platform and **All Day Stores** forms the core of a 1,000-day plan to establish an affordable healthcare footprint across urban and rural India.
*   **Specialized Retail Formats:** All Day Stores are positioned as health and wellness hubs specifically targeting essentials, cosmetics, OTC, and nutraceuticals.
*   **National Footprint:** Objective to secure a pan-India presence across all four geographic zones to ensure universal access to affordable medicine.

## D. Operational Efficiency
*   **Profitability Pivot:** Management is transitioning focus toward enhancing store-level profitability and optimizing operations, signaling a more moderate expansion pace in the near term.
*   **Value-Driven Model:** Business verticals are unified by a tactical approach to deliver affordable healthcare to the Indian mass market.

---

# 5. Manufacturing & Capacity

## A. Key Figures
   *   **Store Sales (Mature):** **₹6 Lakhs - ₹7 Lakhs** Monthly per store (3-5 year maturation)
   *   **Store Count & Performance:** **234** Stores >2 years old · **1% - 1.5%** Underperforming/Loss-making
   *   **Model Margins:** **40% - 55%** FOFO model · **10% - 15%** COCO model
   *   **COCO Gross Margin:** **>70%** Actual (vs. 60% previously indicated)
   *   **New Store Growth:** **~800** FY26 openings · **~100%** Projected Year-2 growth

## B. Store Unit Economics & Scaling
   *   **High-Efficiency Maturation:** Mature locations achieve steady-state revenue with an exceptionally low failure rate among established stores.
   *   **Rapid Growth Trajectory:** Recent large-scale store additions are expected to double their output in the second year, indicating a steep ramp-up curve.
   *   **Operational Footprint:** Standardized store model utilizes a compact **300-400 sq. ft.** footprint and lean staffing of **2-3 employees** per unit.
   *   **Margin Outperformance:** Actual gross margins for company-owned outlets are significantly higher than historical guidance, enhancing the internal rate of return.

## C. Supply Chain & Resource Utilization
   *   **Cost Structure:** Supply chain partner expenses are categorized as sales commissions and remain largely fixed, providing operating leverage as volumes scale.
   *   **Data-Driven Expansion:** SKU growth and molecule additions are optimized via real-time demand signals and prescription trends from a massive network of **2,500 stores**.

---

# 6. Risks & Operational Factors

## A. Key Figures
   *   **MSME Procurement Mix:** **70%** of total sourcing
   *   **Regulatory Payment Terms:** **45 Days** maximum for MSME suppliers

## B. Marketing Visibility
   *   **Underutilized Brand Assets:** Despite securing high-profile ambassadors, concerns persist regarding the lack of **broad-scale amplification** and TV commercial presence.

## C. Regulatory Compliance
   *   **Working Capital Dynamics:** Improved payable cycles are primarily a function of mandatory compliance regulations rather than organic negotiation.

## D. Expansion Moderation
   *   **Strategic Pivot to Profitability:** Management is intentionally decelerating new store openings through **Q2 and Q3 of FY27** to prioritize store-level economics and same-store sales growth (SSG).
   *   **Growth Sustainability Concerns:** The shift away from aggressive expansion has triggered inquiries into whether historical high double-digit growth rates were artificially inflated by footprint scaling.
   *   **Rationalization Timeline:** Underperforming units face a gradual **one-to-two-year** review period, aligned with management’s view that retail viability requires a **three-to-five-year** assessment window.

---

# 7. Guidance & Outlook

## A. Key Figures
   *   **Long-term Store Target:** **5,000+** Davaindia outlets by FY29
   * FY26 Store Expansion: 600–700 new openings (vs. ~800 in previous year)
   *   **FY27 Store Expansion:** **500–700** new openings projected

## B. Strategic Roadmap & Store Network
   *   **Network Scaling:** Management remains committed to aggressive long-term expansion to 5,000+ stores, leveraging high-profile brand associations with **MS Dhoni and Suniel Shetty** to drive visibility.
   *   **Moderated Near-term Pace:** Expansion velocity is expected to slow slightly in the current fiscal compared to last year, with a specific deceleration noted during **Q2 and Q3**.
   *   **Operational Pivot:** The company is shifting focus toward enhancing store-level profitability and operational efficiency over the next **one to two quarters** before re-accelerating.

## C. Revenue & Profitability Trajectory
   *   **Growth Confidence:** While formal numerical guidance for FY27 was withheld, management anticipates a robust growth trajectory sustained by current sequential and year-on-year momentum.
   *   **Scalability Focus:** The business model is being optimized to balance top-line expansion with bottom-line sustainability, ensuring the foundation can support long-term scaling.